These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32542733)

  • 1. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
    Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
    J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
    Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
    Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
    Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
    Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
    Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
    Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
    EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
    De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
    Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
    De Ridder T; Reddell P; Jones P; Brown G; Campbell J
    Front Vet Sci; 2021; 8():764800. PubMed ID: 34977208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
    Gasser K
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2022 Jun; 50(3):225-231. PubMed ID: 35790169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
    Barnett CME; Broit N; Yap PY; Cullen JK; Parsons PG; Panizza BJ; Boyle GM
    Invest New Drugs; 2019 Feb; 37(1):1-8. PubMed ID: 29667135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
    Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
    Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012).
    Pratschke KM; Atherton MJ; Sillito JA; Lamm CG
    J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.
    Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I
    Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of lesions to topical tigilanol tiglate gel.
    Hansen N; Nicholas N; Pack G; Mackie JT; Shipstone M; Munday JS; Reddell P; Orbell G; Malik R
    Vet Med Sci; 2018 Feb; 4(1):53-62. PubMed ID: 29468081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
    De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
    Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer.
    Frimberger AE; Moore AS; Cincotta L; Cotter SM; Foley JW
    Clin Cancer Res; 1998 Sep; 4(9):2207-18. PubMed ID: 9748141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells.
    Antwi FD; Awad T; Larin M; Heesom K; Lewis P; Reddell P; Poghosyan Z; Dewitt S; Moseley R; Knäuper V
    Cells; 2024 Jun; 13(11):. PubMed ID: 38891113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008).
    Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M
    J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
    Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
    J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.